Literature DB >> 7903205

Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.

Y Fujimoto1, L L Hampton, P J Wirth, N J Wang, J P Xie, S S Thorgeirsson.   

Abstract

Aflatoxin B1 has been suggested as a causative agent for a G to T mutation at codon 249 in the p53 gene in human hepatocellular carcinomas (HCC) from southern Africa and Qidong in China. The objective of the present work was to test the hypothesis that exposure to aflatoxin B1 either alone or coincident with other environmental carcinogens might be associated with allelic losses occurring during development of human hepatocarcinogenesis in China. The HCCs were obtained from two different areas in China: Qidong, where exposure to hepatitis B virus (HBV) and aflatoxin B1 is high; and Beijing, where exposure to HBV is high but that of aflatoxin B1 is low. We analyzed the tumors for mutations in the p53 gene and loss of heterozygosity for the p53, Rb, and APC genes and at marker loci on chromosomes 4, 13, and 16. Frequencies of mutation, loss, and aberration (mutation and loss) of the p53 gene in 25 HCCs from Qidong were 60, 58, and 80%, respectively. The frequencies in 9 HCCs from Beijing were 56, 57, and 78%. However, the frequency of a G to T transversion at codon 249 in HCCs from Qidong and Beijing were 52 and 0%, respectively. These data indicate that mutation and/or loss of heterozygosity in the p53 gene, independent of the 249 mutation, play a critical role in the development of hepatitis B virus-associated HCCs in China. Loss of the Rb and APC genes was observed in 44 and 7% of HCCs from Qidong, respectively. Allelic losses on chromosome 4 and especially on chromosome 16 were frequent in HCCs from Qidong but were not observed in HCCs from Beijing, while loss of heterozygosity on chromosome 13 occurred at similar frequency in both Qidong and Beijing. These results show a distinct difference in the pattern of allelic losses between HCCs in Qidong and Beijing and suggest that aflatoxin B1 and/or other environmental carcinogens may contribute to this difference.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7903205

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma.

Authors:  Zhuo-Lin Deng; Yun Ma
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

2.  The dynamics of hepatitis B virus infection.

Authors:  R J Payne; M A Nowak; B S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.

Authors:  C Martins; M A Kedda; M C Kew
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

4.  Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.

Authors:  X R Xu; J Huang; Z G Xu; B Z Qian; Z D Zhu; Q Yan; T Cai; X Zhang; H S Xiao; J Qu; F Liu; Q H Huang; Z H Cheng; N G Li; J J Du; W Hu; K T Shen; G Lu; G Fu; M Zhong; S H Xu; W Y Gu; W Huang; X T Zhao; G X Hu; J R Gu; Z Chen; Z G Han
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 5.  Mechanisms underlying aflatoxin-associated mutagenesis - Implications in carcinogenesis.

Authors:  Amanda K McCullough; R Stephen Lloyd
Journal:  DNA Repair (Amst)       Date:  2019-03-07

6.  Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.

Authors:  Xing-Hua Huang; Lu-Hong Sun; Dong-Dong Lu; Yan Sun; Li-Jie Ma; Xi-Ran Zhang; Jian Huang; Long Yu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

7.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.

Authors:  Zongtang Sun; Taoyang Chen; Snorri S Thorgeirsson; Qimin Zhan; Jianguo Chen; Ju-Hyun Park; Peixin Lu; Chu Chieh Hsia; Nengjin Wang; Libin Xu; Lingling Lu; Fei Huang; Yuanrong Zhu; Jianhua Lu; Zhengping Ni; Qinan Zhang; Yuying Wu; Guoting Liu; Zhiyuan Wu; Chunfeng Qu; Mitchell H Gail
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

Review 8.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

9.  RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.

Authors:  C A Reed; C N Mayhew; A K McClendon; X Yang; A Witkiewicz; E S Knudsen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

10.  Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index.

Authors:  Valérie Paradis; Ivan Bièche; Delphine Dargère; Ingrid Laurendeau; Christophe Laurent; Paulette Bioulac Sage; Claude Degott; Jacques Belghiti; Michel Vidaud; Pierre Bedossa
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.